TrialBritish journal of haematology2026

Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers.

Michael Tveden Gundesen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.